Goldman Sachs
RCKT icon

Goldman Sachs’s Rocket Pharmaceuticals RCKT Stock Holding History

Goldman Sachs’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Hold
140,000
– – ﹤0.01% 5725
2026
Q1 		$501K Buy
+140,000
New +$556K ﹤0.01% 5593

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs's RCKT Position: Q2 2026 in Review

Goldman Sachs increased its Rocket Pharmaceuticals (RCKT) stake by 65% in Q2 2026, buying an estimated $3.7M and bringing the position to 2,833,427 shares worth $9.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3258.

Goldman Sachs first reported a position in RCKT in Q2 2015 and has held it in 40 quarters since. The position peaked at $51.8M in Q4 2020. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Goldman Sachs held 2,833,427 shares of Rocket Pharmaceuticals worth $9.69M as of Q2 2026.
  • Goldman Sachs bought 1,112,311 Rocket Pharmaceuticals shares in Q2 2026, an estimated $3.7M.
  • Rocket Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3258 holding.
  • Goldman Sachs first reported a position in Rocket Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
  • Goldman Sachs's Rocket Pharmaceuticals position peaked at $51.8M in Q4 2020.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.